FIELD: medicine, pharmaceutics.SUBSTANCE: in formula at least one of X and Y represents S, and the other represents O； L represents C1-7alkylene optionally including a heteroatom specified in O, wherein the above alkylene is optionally substituted by one or more substitutes independently specified in OH, C1-6alkyl and C1-6alkoxy； R1 represents hydrogen or 1) a partially substituted 6-merous ring containing one heteroatom specified in N, and optionally containing a carbonyl group； or 2) an aromatic ring system specified in: phenyl, a monocyclic 5- or 6-merous heteroaromatic ring structure containing 1-2 heteroatoms specified in N, and a bicyclic heteroaromatic ring structure containing a 5- or 6-merous heterocycle containing 1-2 heteroatoms specified in N, wherein the above heterocycle is condensed with a benzene ring, wherein the above aromatic ring system is optionally substituted by one or more substitutes optionally specified in halogen, OH, C1-7alkyl, C1-7alkoxy； wherein the above alkoxy is optionally additionally substituted by C1-6alkoxy, and wherein the above alkyl is optionally additionally substituted by hydroxy or C1-6alkoxy； R12 represents hydrogen； provided the above compound is other than 1-(2-isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d]pyrimidin-4-one.EFFECT: invention refers to the new compounds of formula (I), their tautomers or their pharmaceutically acceptable salts, which possess the properties of myeloperoxidase (MPO) inhibitors and are especially effective in treating or preventing neuroinflammatory, cardiovascular and respiratory disorders.22 cl, 1 tbl, 33 exИзобретение относится к новым соединениям формулы (I), их таутомерам или их фармацевтически приемлемым солям, которые обладают свойствами ингибиторов фермента миелопероксидазы (МПО) и являются особенно полезными в лечении или профилактике нейровоспалительных, сердечно-сосудистых и респираторных расстройств. В формуле (I)по меньшей мере один из X и Y представляет собой S,
